• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.03% Nasdaq Up0.29%

    Regeneron Pharmaceuticals, Inc. (REGN)

    423.77 Up 3.56(0.85%) 4:00PM EST
    |After Hours : 423.74 Down 0.03 (0.01%) 5:57PM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Regeneron Pharmaceuticals, Inc.
    777 Old Saw Mill River Road
    Tarrytown, NY 10591
    United States - Map
    Phone: 914-347-7000
    Website: http://www.regeneron.com

    Index Membership:N/A
    Full Time Employees:2,714

    Business Summary 

    Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company’s antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Regeneron Pharmaceuticals, Inc.

    Corporate Governance 
    Regeneron Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jan 1, 2015 is 10. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 10; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Leonard S. Schleifer M.D., Ph.D., 62
    Co-Founder, Chief Exec. Officer, Pres, Exec. Director and Ex Officio Member of Technology Committee
    Dr. Alfred G. Gilman M.D., Ph.D., 73
    Co-Founder, Director, Chairman of Corp. Governance & Compliance Committee and Member of Technology Committee
    Mr. Robert E. Landry Jr., 51
    Chief Financial Officer and Sr. VP of Fin.
    Mr. George D. Yancopoulos M.D., Ph.D., 55
    Chief Scientific Officer, Exec. VP, Director, Ex Officio Member of Technology Committee and Pres of Regeneron Research Laboratories
    Dr. Neil Stahl Ph.D., 58
    Sr. VP of R&D Sciences
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders